[{"id":"1394e99e-c38f-44e4-ab4d-aee1d10301bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507541","created_at":"2022-08-19T17:10:01.039Z","updated_at":"2025-02-25T12:28:56.881Z","phase":"Phase 2","brief_title":"TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05507541","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive","tags":["PD-L1 • ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-24"},{"id":"cc241a5c-7c68-406b-b95d-f9f314fccafd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03939182","created_at":"2021-02-03T10:56:06.215Z","updated_at":"2024-07-02T16:34:36.776Z","phase":"Phase 1","brief_title":"Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma","source_id_and_acronym":"NCT03939182","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BCL6 • IRF4 • MME","pipe":"","alterations":" ","tags":["BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • abexinostat (CG-781)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/29/2019","start_date":" 05/29/2019","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-10"},{"id":"f2fcd14a-57d9-48b4-b1ec-e72fc82dbb8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03731234","created_at":"2022-12-28T18:58:42.454Z","updated_at":"2024-07-02T16:34:59.344Z","phase":"Phase 2","brief_title":"Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance","source_id_and_acronym":"NCT03731234","lead_sponsor":"Fondazione Italiana Linfomi - ETS","biomarkers":" IRF4","pipe":"","alterations":" ","tags":["IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/02/2019","start_date":" 07/02/2019","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-04"},{"id":"b73496d5-e698-47e5-b7a2-1ea85e0d187e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696784","created_at":"2021-01-18T18:07:07.182Z","updated_at":"2024-07-02T16:35:07.400Z","phase":"Phase 1","brief_title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","source_id_and_acronym":"NCT03696784","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2043","study_completion_date":" 03/22/2043","last_update_posted":"2024-04-26"},{"id":"9c9271f5-1a7e-4c0e-a836-6adeffa127dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04223765","created_at":"2021-04-23T04:56:25.788Z","updated_at":"2024-07-02T16:35:08.115Z","phase":"Phase 1","brief_title":"Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.","source_id_and_acronym":"NCT04223765","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 03/22/2028","primary_completion_date":" 03/22/2028","study_txt":" Completion: 03/22/2043","study_completion_date":" 03/22/2043","last_update_posted":"2024-04-23"},{"id":"f7ccd756-4413-4530-bc65-1188b9dc3cbc","acronym":"DIAL","url":"https://clinicaltrials.gov/study/NCT03038672","created_at":"2021-01-18T14:57:44.271Z","updated_at":"2024-07-02T16:35:20.479Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas","source_id_and_acronym":"NCT03038672 - DIAL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TMB • BCL2 • BCL6 • CD27 • IRF4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD27 expression","tags":["ALK • TMB • BCL2 • BCL6 • CD27 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD27 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 10/25/2024","study_completion_date":" 10/25/2024","last_update_posted":"2024-02-07"},{"id":"8a4f4c76-2dc0-425a-a17a-009310b1b1fb","acronym":"IELSG37","url":"https://clinicaltrials.gov/study/NCT01599559","created_at":"2021-01-18T06:50:23.394Z","updated_at":"2024-07-02T16:35:32.505Z","phase":"Phase 3","brief_title":"Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma","source_id_and_acronym":"NCT01599559 - IELSG37","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" BCL2 • CD20 • TNFRSF8 • BCL6 • PTPRC • IRF4 • MME","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • CD20 • TNFRSF8 • BCL6 • PTPRC • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 12/17/2029","study_completion_date":" 12/17/2029","last_update_posted":"2023-10-19"},{"id":"883c093f-d2f2-4bdb-a6df-2c4fb2930bc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05890352","created_at":"2023-06-06T14:06:56.792Z","updated_at":"2024-07-02T16:35:34.556Z","phase":"Phase 2","brief_title":"Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment","source_id_and_acronym":"NCT05890352","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" MYC • BCL2 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Brukinsa (zanubrutinib) • Tazverik (tazemetostat) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2023-10-05"},{"id":"93766317-3ff9-4f80-ade3-ee042661108f","acronym":"ARCHED","url":"https://clinicaltrials.gov/study/NCT05820841","created_at":"2023-04-20T14:03:42.227Z","updated_at":"2025-02-25T15:00:51.328Z","phase":"Phase 3","brief_title":"Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05820841 - ARCHED","lead_sponsor":"Universität des Saarlandes","biomarkers":" ALK • BCL2 • CD20 • BCL6 • IRF4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • CD20 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-08-31"},{"id":"a86eae23-5fcb-4a8b-a5e6-a0ef3b33f450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02213913","created_at":"2021-01-18T10:22:23.451Z","updated_at":"2024-07-02T16:35:49.349Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","source_id_and_acronym":"NCT02213913","lead_sponsor":"University of Chicago","biomarkers":" MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 07/29/2014","start_date":" 07/29/2014","primary_txt":" Primary completion: 07/29/2023","primary_completion_date":" 07/29/2023","study_txt":" Completion: 07/29/2023","study_completion_date":" 07/29/2023","last_update_posted":"2023-04-28"},{"id":"d9ee35f4-da43-4d95-b8e1-d4bff5818692","acronym":"","url":"https://clinicaltrials.gov/study/NCT05202782","created_at":"2022-01-24T17:01:38.564Z","updated_at":"2024-07-02T16:36:06.205Z","phase":"Phase 2","brief_title":"Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma","source_id_and_acronym":"NCT05202782","lead_sponsor":"Northwestern University","biomarkers":" BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 10/09/2026","primary_completion_date":" 10/09/2026","study_txt":" Completion: 10/09/2029","study_completion_date":" 10/09/2029","last_update_posted":"2022-08-03"},{"id":"1789cc12-961a-49eb-8333-f81546d48f76","acronym":"","url":"https://clinicaltrials.gov/study/NCT04425824","created_at":"2021-01-18T21:19:11.424Z","updated_at":"2024-07-02T16:36:44.192Z","phase":"Phase 2","brief_title":"Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04425824","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" PD-L1 • MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" PD-L1 expression • CD20 positive","tags":["PD-L1 • MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2020-06-16"},{"id":"1ea1ca68-2f8e-4f15-a31f-eeb0fc3d6cc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01670370","created_at":"2021-01-18T07:13:33.891Z","updated_at":"2024-07-02T16:37:02.806Z","phase":"Phase 2","brief_title":"Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.","source_id_and_acronym":"NCT01670370","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-02-15"},{"id":"16ca5151-fe92-45a1-a64d-f67978d14883","acronym":"","url":"https://clinicaltrials.gov/study/NCT03399747","created_at":"2021-01-18T16:46:40.550Z","updated_at":"2024-07-02T16:37:14.871Z","phase":"Phase 2","brief_title":"Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT03399747","lead_sponsor":"Asan Medical Center","biomarkers":" BCL2 • CD20 • BCL6 • CD5 • IRF4 • MME","pipe":"","alterations":" ","tags":["BCL2 • CD20 • BCL6 • CD5 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisolone"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 12/07/2016","start_date":" 12/07/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2018-01-16"},{"id":"33e3937e-a553-491a-80be-23cbf4d56ba4","acronym":"SWOG-S8809/S9800","url":"https://clinicaltrials.gov/study/NCT00896922","created_at":"2022-01-26T18:53:52.170Z","updated_at":"2024-07-02T16:37:24.891Z","phase":"","brief_title":"S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911","source_id_and_acronym":"NCT00896922 - SWOG-S8809/S9800","lead_sponsor":"Southwest Oncology Group","biomarkers":" IRF4","pipe":"","alterations":" ","tags":["IRF4"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 10/01/2009","study_completion_date":" 10/01/2009","last_update_posted":"2017-02-28"},{"id":"f63a7e1f-3ff4-4374-bcb2-6ae04e50efbd","acronym":"PRO-R-IPI","url":"https://clinicaltrials.gov/study/NCT01369784","created_at":"2021-01-18T05:36:38.960Z","updated_at":"2024-07-02T16:37:32.697Z","phase":"","brief_title":"Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT01369784 - PRO-R-IPI","lead_sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","biomarkers":" TP53 • BCL2 • BCL6 • IRF4 • LXN","pipe":" | ","alterations":" BCL2 expression • TP53 expression • IRF4 expression","tags":["TP53 • BCL2 • BCL6 • IRF4 • LXN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • TP53 expression • IRF4 expression"],"overall_status":"Completed","enrollment":" Enrollment 158","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2016-04-18"}]